^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ER negative

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
Entrez ID:
3d
Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
4d
Postoperative radiotherapy for ductal carcinoma in situ: survival prediction and clinical decision support using a nomogram-based approach. (PubMed, Sci Rep)
Our study suggests that postoperative RT is associated with improved survival in most DCIS patients. The nomograms showed good performance in predicting the DSS and DFS of DCIS patients, and our online tool well visualized the DSS and DFS prediction to support clinical decision-making.
Journal
|
ER (Estrogen receptor)
|
ER negative
4d
Retrospective analysis of the correlation between MRP2 expression in circulating tumor cells and molecular characteristics of breast cancer. (PubMed, Medicine (Baltimore))
In conclusion, the present investigation reveals a noteworthy correlation between elevated levels of MRP2 protein in CTCs and TNBC. This finding deepens our understanding of the molecular mechanisms that contribute to the metastasis of breast cancer and provides a scientific basis for predicting treatment outcomes in breast cancer patients exhibiting elevated levels of MRP2 protein expression.
Observational data • Retrospective data • Journal • Circulating tumor cells
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative
6d
The clinical pathological significance of TLSs in HER2-low breast cancer. (PubMed, Pathol Res Pract)
In HER2-low breast cancer, TLSs were associated with higher histological grade, the presence of DCIS, absence of lymphovascular invasion, as well as expression of ER negative, PR negative, HER2 2 + , high K-i67, and triple-negative breast cancer. Additionally, the clinical prognosis value of TLSs (such as DFS) exhibited a correlation with the patient's age.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative
7d
TRICIA: TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence (clinicaltrials.gov)
P=N/A, N=130, Recruiting, Jewish General Hospital | Trial completion date: Jun 2023 --> Dec 2027 | Trial primary completion date: Jun 2022 --> Dec 2027
Trial completion date • Trial primary completion date • Liquid biopsy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative
8d
DOT1L inhibition exerts the anti-tumor effect by activating interferon signaling in breast cancer cells. (PubMed, Clin Epigenetics)
These findings suggest that the anti-breast cancer effect of DOT1L inhibition is mediated by multiple mechanisms, including activation of innate immune signaling.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • STING (stimulator of interferon response cGAMP interactor 1) • DOT1L (DOT1 Like Histone Lysine Methyltransferase)
|
HER-2 positive • ER positive • HER-2 negative • HER-2 expression • ER negative • ER positive + HER-2 negative • HER-2 negative + ER positive
|
pinometostat (EPZ-5676)
10d
Estrogen Receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer. (PubMed, J Clin Invest)
Remarkably, the LCOR-ERα disruption converts HR+BC immune-cold tumors into immune-hot tumors responsive to ICB by increased antigen presentation machinery (APM) expression, immune infiltration, T cell recognition and mediated killing. In conclusion, ERα inhibition and the disruption of LCOR to ERα represent a novel therapeutic strategy and an opportunity to elicit immunotherapeutic benefit in HR+BC patients.
Journal • IO biomarker
|
ER (Estrogen receptor)
|
HR positive • ER negative
11d
Protocol to Establish Estrogen Receptor-Negative Heterozygous BRCA1 Organoids. (PubMed, Methods Protoc)
We confirmed that these organoids are unresponsive to estrogen, can self-renew, and express the stem/progenitor marker CD44. In addition, we observed that these organoids contain outgrowths that resemble the mature ductal and lobular units of the mammary gland, thus making it a suitable model system to study how cancer develops in ER/PR/HER2-negative mammary cells that carry a BRCA1 germline mutation.
Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset) • CD44 (CD44 Molecule)
|
HER-2 negative • ER negative • BRCA mutation
11d
Prioritizing context-specific genetic risk mechanisms in 11 solid cancers. (PubMed, medRxiv)
These findings advance our understanding of genetic susceptibility to different cancers. Future work in larger, more diverse GWAS, coupled with more comprehensive annotation atlases, is essential to expand upon and validate our results.
Journal
|
ER (Estrogen receptor)
|
ER negative
11d
Estrogen Signaling During Abrupt Involution Leads to Long-Term Metabolic Dysfunction Similar to Estrogen Receptor Negative Breast Cancer. (PubMed, bioRxiv)
Subset of AI mice had long-term sustained release tamoxifen placed subscapular on day 8 postpartum...Early metabolic phenotypes in AI and GI glands may be caused by differences in adipocyte repopulation related to estrogen signaling. Long-term metabolic effects of AI lead to similar metabolic effects found in breast cancer.
Journal
|
ER (Estrogen receptor)
|
ER negative
|
tamoxifen
11d
Unveiling the traits of HER2-low breast cancer: a comparative analysis of IHC1+ vs IHC2+/ISH-negative subgroups - insights from a 3-year cohort study. (PubMed, Front Oncol)
Despite similar clinicopathological features, IHC2+/ISH- status was independently associated with lower pCR rates compared to IHC1+. These findings suggest that HER2-low subgroups may influence response to NACT and should be considered in multivariable prediction models, potentially informing stratified treatment approaches in the era of anti-HER2 ADCs.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 expression • HER-2 underexpression • ER negative
12d
Synthetic MRI Parameters and Breast Cancer Heterogeneity: A Quantitative Study. (PubMed, Acad Radiol)
SyMRI-derived quantitative metrics are associated with both pathological and imaging features. Effect size analysis highlights histological grade as the most influential confounding factor in the interpretation of quantitative SyMRI.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER negative